Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,454 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1 study).
Takahashi Y, Nomoto H, Yokoyama H, Takano Y, Nagai S, Tsuzuki A, Cho KY, Miya A, Kameda H, Takeuchi J, Taneda S, Kurihara Y, Atsumi T, Nakamura A, Miyoshi H; SWITCH-SEMA 1 study group. Takahashi Y, et al. Among authors: yokoyama h. Diabetes Obes Metab. 2023 Jun;25(6):1503-1511. doi: 10.1111/dom.14998. Epub 2023 Feb 28. Diabetes Obes Metab. 2023. PMID: 36722623 Clinical Trial.
Combined Effects of Energy Intake and Physical Activity on Obesity in Japanese Patients with Type 2 Diabetes (JDDM 50): A Cross-Sectional Study.
Hatta M, Fujihara K, Morikawa SY, Takeda Y, Ishii D, Horikawa C, Kato M, Yokoyama H, Kurihara Y, Iwasaki K, Miyazawa K, Yamazaki K, Tanaka S, Maegawa H, Sone H. Hatta M, et al. Among authors: yokoyama h. Diabetes Ther. 2019 Jun;10(3):1133-1138. doi: 10.1007/s13300-019-0610-x. Epub 2019 Apr 3. Diabetes Ther. 2019. PMID: 30945130 Free PMC article.
Favourable effect of the sodium-glucose co-transporter-2 inhibitor canagliflozin plus the dipeptidyl peptidase-4 inhibitor teneligliptin in combination on glycaemic fluctuation: An open-label, prospective, randomized, parallel-group comparison trial (the CALMER study).
Cho KY, Nomoto H, Nakamura A, Kawata S, Sugawara H, Takeuchi J, Nagai S, Tsuchida K, Omori K, Yokoyama H, Manda N, Kurihara Y, Aoki S, Atsumi T, Miyoshi H. Cho KY, et al. Among authors: yokoyama h. Diabetes Obes Metab. 2020 Mar;22(3):458-462. doi: 10.1111/dom.13879. Epub 2019 Oct 13. Diabetes Obes Metab. 2020. PMID: 31486230 Free PMC article. Clinical Trial.
Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin.
Miya A, Nakamura A, Cho KY, Kawata S, Nomoto H, Nagai S, Sugawara H, Taneda S, Tsuchida K, Omori K, Yokoyama H, Takeuchi J, Aoki S, Kurihara Y, Atsumi T, Miyoshi H. Miya A, et al. Among authors: yokoyama h. J Diabetes Investig. 2021 Aug;12(8):1395-1399. doi: 10.1111/jdi.13479. Epub 2021 Jan 21. J Diabetes Investig. 2021. PMID: 33325645 Free PMC article. Clinical Trial.
Improved time in range and postprandial hyperglycemia with canagliflozin in combination with teneligliptin: Secondary analyses of the CALMER study.
Cho KY, Nomoto H, Nakamura A, Kawata S, Sugawara H, Takeuchi J, Nagai S, Omori K, Tsuchida K, Miya A, Shigesawa I, Tsuchida K, Yanagiya S, Kameda H, Yokoyama H, Taneda S, Kurihara Y, Aoki S, Nishimoto N, Atsumi T, Miyoshi H. Cho KY, et al. Among authors: yokoyama h. J Diabetes Investig. 2021 Aug;12(8):1417-1424. doi: 10.1111/jdi.13498. Epub 2021 Feb 5. J Diabetes Investig. 2021. PMID: 33421309 Free PMC article. Clinical Trial.
Effects of Switching from Liraglutide or Dulaglutide to Subcutaneous Semaglutide on Glucose Metabolism and Treatment Satisfaction in Patients with Type 2 Diabetes: Protocol for a Multicenter, Prospective, Randomized, Open-Label, Blinded-Endpoint, Parallel-Group Comparison Study (The SWITCH-SEMA 1 Study).
Nomoto H, Oba-Yamamoto C, Takahashi Y, Takeuchi J, Nagai S, Yokoyama H, Taneda S, Kurihara Y, Aoki S, Kameda H, Cho KY, Nakamura A, Atsumi T, Miyoshi H. Nomoto H, et al. Among authors: yokoyama h. Diabetes Ther. 2021 Mar;12(3):955-964. doi: 10.1007/s13300-020-00986-9. Epub 2021 Jan 24. Diabetes Ther. 2021. PMID: 33491111 Free PMC article.
Trends in glycemic control in patients with insulin therapy compared with non-insulin or no drugs in type 2 diabetes in Japan: a long-term view of real-world treatment between 2002 and 2018 (JDDM 66).
Yokoyama H, Araki SI, Yamazaki K, Kawai K, Shirabe SI, Oishi M, Kanatsuka A, Yagi N, Kabata D, Shintani A, Maegawa H; JDDM study group. Yokoyama H, et al. BMJ Open Diabetes Res Care. 2022 May;10(3):e002727. doi: 10.1136/bmjdrc-2021-002727. BMJ Open Diabetes Res Care. 2022. PMID: 35504696 Free PMC article.
Effects of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide on glucose metabolism in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, parallel-group comparison study (the SWITCH-SEMA 2 study).
Nomoto H, Furusawa S, Nakamura A, Takeuchi J, Nagai S, Yokoyama H, Sakuma I, Taneda S, Kurihara Y, Aoki S, Miya A, Kameda H, Cho KY, Atsumi T, Miyoshi H. Nomoto H, et al. Among authors: yokoyama h. BMJ Open. 2022 May 18;12(5):e056885. doi: 10.1136/bmjopen-2021-056885. BMJ Open. 2022. PMID: 35584872 Free PMC article.
2,454 results